Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome
Aims: In our single-center retrospective study we evaluated whether level of different checkpoint molecules in bone marrow biopsies at diagnosis affect the clinical course of patients with myelodysplastic syndrome (MDS). Methods and results: A consecutive cohort of 55 MDS patients treated in our cen...
Main Authors: | Nikolai Tcvetkov, Artem Gusak, Elena Morozova, Ivan Moiseev, Vadim Baykov, Maria Barabanshikova, Kirill Lepik, Evgenyi Bakin, Julia Vlasova, Anna Osipova, Ludmila Zubarovskaya, Boris Afanasyev |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Leukemia Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048920300212 |
Similar Items
-
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
by: Francesco D'Alò, et al.
Published: (2010-08-01) -
Emerging Therapies for the Myelodysplastic Syndromes
by: Jonathan Canaani
Published: (2019-12-01) -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
by: Mariangela Greco, et al.
Published: (2010-05-01) -
High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndrome.
by: Ivan Sergeevich Moiseev, et al.
Published: (2021-01-01) -
Prognostic Value of Next-Generation Sequencing Data in Patients with Myelodysplastic Syndrome
by: NYu Tsvetkov, et al.
Published: (2019-03-01)